Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Microbiology

Background:

• Tuberculosis remains a significant global health threat.
• Novel therapeutic agents are urgently needed to combat Mycobacterium tuberculosis.
• Heterocyclic compounds are a promising scaffold for drug discovery.

Purpose of the Study:

• To synthesize and evaluate novel five-membered heterocyclic compounds against Mycobacterium tuberculosis.
• To identify potent anti-tubercular agents with favorable physicochemical properties.
• To elucidate the mechanism of action and identify the molecular target of active compounds.

Main Methods:

• Synthesis of 49 five-membered heterocyclic compounds (pyridine- and pyrrole-type nitrogen).
• Antimicrobial susceptibility testing to determine minimum inhibitory concentrations (MICs).
• In vivo efficacy studies in a mouse model of tuberculosis.
• Generation of resistant mutants and whole-genome sequencing to identify drug targets.

Main Results:

• 1,3,5-trisubstituted pyrazoles (compounds 5-49) demonstrated low micromolar MICs against Mycobacterium tuberculosis.
• Selected pyrazoles exhibited improved physicochemical profiles and no cytotoxic effects.
• Compound 6 significantly reduced lung bacterial burden in a mouse tuberculosis model.
• Whole-genome sequencing identified mutations in the mmpL3 gene in resistant strains, suggesting it as the drug target.

Conclusions:

• Novel 1,3,5-trisubstituted pyrazoles are potent inhibitors of Mycobacterium tuberculosis.
• Compound 6 represents a promising lead candidate for tuberculosis treatment.
• The mmpL3 gene is a validated target for this class of anti-tubercular agents.